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Abstract
Impaired axonal transport has been linked to the pathogenic processes of Alzheimer’s disease
(AD) in which axonal swelling and degeneration are prevalent. The development of non-invasive
neuroimaging methods to quantitatively assess in vivo axonal transport deficits would be
enormously valuable to visualize early, yet subtle, changes in the AD brain, to monitor the disease
progression and to quantify the effect of drug intervention. A triple transgenic mouse model of AD
closely resembles human AD neuropathology. In this study, we investigated age-dependent
alterations in the axonal transport rate in a longitudinal assessment of the triple transgenic mouse
olfactory system, using fast multi-sliced T1 mapping with manganese-enhanced MRI. The data
show that impairment in axonal transport is a very early event in AD pathology in these mice,
preceding both deposition of Aβ plaques and formation of Tau fibrils.
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Introduction
Neuronal cell function and viability critically depend on effective and timely axonal
transport (AT), i.e. the process in which intracellular cargoes including neurotransmitters,
proteins and organelles are trafficked through axons to the nerve terminals. Axonal transport
deficits have been implicated in neurodegenerative diseases such as Alzheimer’s disease
(AD) (Morfini et al. 2009; Wilson 2008). Two major pathological hallmarks of AD,
accumulation of β-amyloid (Aβ) deposition in plaques and fibrillization of Tau, appear to
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cause axonopathy. Tau is a microtubule-associated protein that stabilizes and is essential for
maintaining normal axonal transport processes (Gotz et al. 2006). The dysregulation of
axonal transport leads to synaptic dysfunction and synaptic/neuronal loss in animal models
of AD. The presence of axonopathy in human AD has been supported by findings of axonal
swelling, accumulated mitochondrial components in lysosomes, accumulation of vesicles in
cell bodies, and dysfunctional synaptic vesicles at nerve terminals (Gotz et al. 2006; Stokin
et al. 2005).
Increased axonopathy has been reported in animal models of amyloidosis including the
Tg2576 mouse that over-expresses a mutant human amyloid precursor protein (APP) and an
APP mutant mouse that also that also expresses a human presenilin mutation (PS1) (Smith et
al. 2007; Wirths et al. 2007). It has been suggested that the axonal transport deficits are
occurring in conjunction with the accumulation of insoluble Aβ and prior to Aβ plaque
formation in the Tg2576 AD mouse model. Many of the transgenic AD mouse models
exhibit axonal swelling that likely interferes with normal axonal transport of essential
cellular components, mitochondria, and other vesicles. Mutations in the Tau gene also
seriously disrupt microtubule function and lead to dystrophic axonal processes (Hutton et al.
1998; Spillantini et al. 1998). However, the mechanisms by which both aging and various
genetic insults disrupt axonal transport have not been clearly delineated (De Vos et al. 2008;
Morfini et al. 2009; Schindowski et al. 2007). Therefore, understanding the role of Aβ and
Tau in the development of axonal transport deficits in AD brain is crucial for developing
new strategies in early diagnosis and possible treatments to slow progression of AD
pathology.
Axonal transport rates have conventionally been measured in vitro using radiotracers or
fluorescent dyes in excised neurons. These conventional methods are invasive and cannot be
used in vivo. Recently in vivo approaches to measuring axonal transport rates have been
reported using magnetic resonance imaging (MRI) methods. One commonly used form of
MRI, manganese-enhanced magnetic resonance imaging (MEMRI), involves application of
manganese chloride (MnCl2) as a contrast agent to follow axonal transport. MEMRI
measures the shortening of the longitudinal relaxation rate constant (R1 = 1/T1) over time
after administering an MnCl2 solution (Chuang et al. 2006; Kim et al. 2009). Manganese ion
(Mn2+) is a paramagnetic, calcium analogue that has been used as a contrast agent in MRI. It
is a trans-synaptic tracer that is taken up into neurons via voltage-gated calcium channels,
packaged into vesicles, and transported down the axon in a microtubule-dependent manner.
After being released from pre-synaptic terminals, Mn2+ crosses the synapse, enters post-
synaptic neurons, and is distributed through interconnecting brain areas by selective
anterograde transport. In a series of papers, Pautler and co-workers established MEMRI as a
viable neuronal tract tracing method that allows for the measurement of axonal transport
rates (Pautler et al. 1998; Pautler et al. 2002; Pautler 2004). Given that aging is the major
risk factor for AD, it is worth noting that axonal transport rates in the CNS of rats, measured
using MEMRI, decrease with normal aging (Cross et al. 2008).
Currently, most MEMRI studies rely on T1w MEMRI methods to detect changes in signal
enhancement from Mn2+ accumulation (Serrano et al. 2008; Smith et al. 2007). However,
MRI contrast in T1w MEMRI methods can only be useful for a narrow range of Mn2+
concentration in the target tissue. In addition, quantification of T1w MEMRI is not reliable
for multi-session or longitudinal studies due to variations in the signal intensity by other
contributing factors such as flip angle and base line T1 values. Unlike T1w MEMRI, the
parametric T1 mapping method provides reliable quantification as the signal sensitivity does
not depend on the Mn2+ concentration. The T1 mapping method also allows the Mn2+
contrast comparison in multiple sessions because this method does not require a
normalization process. In this study, we have used our previously-developed fast multi-slice
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Look-Locker sequence with multiple phase encodings per inversion pulse, which enabled T1
mapping in short acquisition time (Lee 2007).
The olfactory system is particularly favorable for the study of axonal transport since Mn2+
can be delivered noninvasively. The delivery of Mn2+ into mouse olfactory epithelium can
easily be achieved via injection of MnCl2 solution through the nasal pathway as it connects
primary neurons in the epithelium to cortical projections without necessitating transport of
tracers across the blood-brain barrier (Cross et al. 2004; Cross et al. 2008). Successful
measurement of an axonal transport deficit has been achieved in the olfactory system of an
APP transgenic mouse model of AD using the MEMRI technique (Smith et al. 2007; Wirths
et al. 2007).
In this study, we have used an animal model of AD that expresses both Aβ and Tau
pathology, a triple transgenic mouse model of AD (3xTg-AD). The 3xTg-AD is a widely
used as an animal model for human AD because it expresses mutations in PS1M146V,
APPSwe, and TauP301L, leading to both Aβ and Tau pathology (Oddo et al. 2003). The
3xTg-AD mice develop Aβ and Tau pathologic lesions in a sequential manner. By
measuring axonal transport deficits in this mouse model at different ages, we investigated
the effects of the combination of Aβ and Tau aggregates on axonal transport at an early
stage of the disease development in these mice. We hypothesize that occurrence of early
axonal transport deficits is likely due to intraneuronal Aβ first, followed by Tau hyper-
phosphorylation and fibrillization, leading to progressive axonal transport deficits. Using
quantitative T1 mapping rather than qualitative T1w imaging together with non-invasive
MEMRI, we demonstrate that these methods can be reliably employed to detect age-
dependent axonal transport impairments.
Materials and Methods
Animals
All the animals were handled in compliance with institutional and national regulations and
policies. The protocols were approved by the Institutional Animal Care and Use Committee.
3xTg-AD mice were obtained from the mouse colony established at the University of
Kansas from a breeding pair obtained from Dr. Laferla at the University of California at
Irvine. 3xTg-AD mice harbor PS1M146V, APPSwe, and TauP301L and progressively develop
both Aβ plaques and NFT pathology with accompanying neuronal death in brain regions
similar to those seen in human AD. These animals develop intracellular Aβ pathology in
neocortex at 3 months of age, extracellular Aβ pathology in frontal cortex at 6 months, and
Tau pathology at 12 months. The presence of both Tau and APP transgenes in olfactory bulb
(OB) has been confirmed by Western blotting (Oddo et al. 2003).
Three age groups of 3xTg-AD mice and age-matched wt mice were studied: 2 months (2
mos), n = 9 for wt and n=8 for 3xTg-AD; 3 months (3 mos), n = 8 for wt and n = 4 for 3xTg-
AD; 15 months (15 mos) of age, n = 5 for wt and n = 6 for 3xTg-AD.
Manganese (Mn2+) Administration
Animals were anesthetized with 4% isoflurane mixed in 4 L/min air and 1 L/min O2 for 5
min. Manganese chloride (MnCl2) solution was administered intranasally. A nasal lavage of
4 μL of isotonic MnCl2 solution (160 mM) (Sigma-Aldrich, St. Louis, MO) was
administered to the left nostril using a Hamilton syringe (Hamilton Company, Reno, NV).
Animals were then returned to a fresh cage on a heating pad, stimulated using amyl acetate
for 15 min to enhance uptake of Mn2+ in the olfactory neurons, and allowed to recover fully
before MRI sessions. We chose unilateral administration of MnCl2 solution to reduce the
dosage of the MnCl2 solution to limit possible toxicity and to facilitate confirmation of the
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successful administration of MnCl2 by comparing signal enhancements in the ipsilateral and
contralateral turbinate.
Magnetic resonance imaging
All MR studies were performed using a 9.4 T Varian INOVA system (Varian Inc., CA),
equipped with a 12 cm gradient coil (40 G/cm, 250 μs). A 6 cm diameter Helmholtz volume
transmit coil and a 7 mm diameter surface receive coil with de-tune capability were used for
MR imaging. Animals were anesthetized and maintained with 1 - 1.5 % isoflurane during
MRI sessions. Mice were under anesthesia for less than 40 min for each MRI session. Core
body temperature was maintained at 37 °C using a circulating hot water pad and a
temperature controller (Cole-Palmer, NY). Respiration was monitored via a pressure pad
under the animal (SA Instruments, NY). MR data were acquired before and 1h, 6h, and 24h
after unilateral and intranasal administration of MnCl2 solution in four separate MRI
sessions. These four MRI time points were chosen based on the time course of the R1
changes in the olfactory bulb (OB) and lateral olfactory tracts (LOT) after intranasal MnCl2
administration (data not shown). The data showed that R1 in the OB changed linearly with
time from 1h to up to 6h post MnCl2 administration. Therefore, 1h and 6h time points were
chosen to calculate axonal transport rates, to remove the effect of the initial transport delay
from the turbinate to the OB, and to achieve high detectability R1 changes in OB by
allowing enough time for transported Mn2+ to accumulate in the OB. The 24h time point
was chosen to provide enough time for axonal transport of Mn2+ to the more distal LOT.
T1 maps were measured using a non echo planar imaging based, multi-slice T1 sequence
modified from the Look-Locker sequence (Look et al. 1970) to acquire two phase encodings
per inversion pulse (TR/TE = 4/2 ms, FOV = 2 cm, matrix = 128 × 128, thickness = 0.5 mm,
flip angle = 20°, 22 inversion times from 40 – 5470 ms, and acquisition time = 8.5 min). B1
maps were measured to correct the effect of flip angle variations on T1 maps (TR/TE =
200/3.7 ms, matrix = 128 × 128, NEX = 4, thickness = 0.5 mm) (Pan et al. 1998). High
resolution T1-weighted (T1w) spin-echo images were also acquired to visualize turbinate
areas of the olfactory system (TR/TE = 600/10 ms, NEX = 2, matrix = 256 × 256, thickness
= 0.45 mm, scan time = 5 min).
MEMRI Data Analysis
The T1 and B1 values of each pixel were calculated using a program written in IDL (RSI,
CO). The R1 values were calculated based on the following equation:
Eq. (1)
where T1 * is the apparent T1 obtained from the fitting of inversion recovery signal
intensities using the Levenberg-Marquardt algorithm, τ is the duration between successive
excitations of the same slice, and θ is flip angle. Ideally, if the exact flip angle at each pixel
is known, the T1 can be computed from Eq. (1) after obtaining T1 * without further
information. However, the B1 field inhomogeneity from the imperfect excitation pulse and
the RF coil profile causes the flip angle to differ from the intended value. Therefore, B1 field
maps were used to obtain the actual flip angle value, θ in Eq. (1) in a pixel-by-pixel basis.
Region of interest (ROI) analysis was performed using STIMULATE software (Strupp
1996). Axonal transport rate index (ATRI) of olfactory sensory neurons was calculated from
the R1 changes in an ROI of olfactory bulb between 1h and 6h after MnCl2 administration
((R1(6h) – R1(1h))/5). ATRI at the LOT was estimated from the time course of R1 changes in
an ROI of the LOT between pre and post 24h MnCl2 administration ((R1(24h) – R1(pre))/24).
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Mn2+ uptake in the turbinate was compared between wt and 3xTg-AD mice at 1h post
MnCl2 administration. The MR signal intensity in the spin-echo T1w images was measured
from both enhanced (left, L) and non-enhanced (right, R) sides of the turbinate. Unlike
gradient-echo based T1 mapping methods, spin-echo T1w MEMRI does not suffer from the
macroscopic susceptibility induced signal loss where the susceptibility effect is pronounced
due to the air and tissue interface, such as the turbinate regions. The MR signal intensity
ratio between two sides at 1h post MnCl2 administration provided an index for Mn2+ uptake.
Trans-synaptic transmission efficiency index of Mn2+ was estimated from the ATRI at the
OB and LOT. Since the concentration of Mn2+ at LOT is proportional to the concentration
in the OB and the efficiency of synaptic transmission from the olfactory sensory neurons to
mitral cells in the OB glomeruli, the trans-synaptic transmission efficiency index was
calculated by the ratio of the ATRIs at LOT and OB.
Two-tailed Student t-tests were performed to compare group means of ATRIs using
Microsoft Excel. All data are presented as mean ± SD. A P-value of less than 0.05 was
considered statistically significant.
Results
High resolution MEMRI of the 3xTg-AD mouse brain
The coronal Mn2+ enhanced T1w MR image (T1w MEMRI) clearly shows structures and
layers of the nasal and olfactory system of the 3xTg-AD mouse (Fig. 1A Top). The T1w
MEMRI was acquired at 6h post MnCl2 administration in a 5 min data acquisition time and
demonstrates the Mn2+ accumulation from the turbinate to the OB. Three major areas (i:
turbinate; ii: OB; iii: LOT in Fig. 1A (Top: coronal MRI, Bottom: sagittal MRI)) were
chosen to calculate axonal transport rates from the turbinate to the OB, and from the
turbinate to the LOT. The first slice position (i in Fig. 1A) was placed where olfactory
sensory neurons are located in the olfactory epithelium of the turbinate. The second slice
position (ii) was placed where olfactory neurons project to glomeruli in the olfactory bulbs.
The third slice position (iii) was placed where olfactory output neurons (mitral cells) are
receiving inputs from glomeruli and projecting to various targets in the brain via olfactory
tracts. Mn2+ accumulates following the olfactory neural circuits from olfactory sensory
neurons to olfactory tracts, and MEMRI were measured at 1h, 6h, and 24 h post MnCl2
administration through the left nasal cavity.
Mn2+ uptake in the turbinate at 1h post MnCl2 administration
High resolution T1w MEMRI of the turbinate (Fig. 1B(i)) was acquired at 1h post MnCl2
administration. Unilateral MR signal enhancement in the left turbinate (marked by red
arrow) shows the structure in detail, including nasal cavities. The signal enhancement in the
turbinate indicates Mn2+ uptake into the olfactory sensory neurons during the initial hour.
There was no difference in signal enhancement between wt and 3xTg-AD mice in any age, 2
mos, 15 mos or 18 mos of age (p = 0.57, n = 5 for wt and n = 6 for 3xTg-AD).
Mn2+ transport in the OB at 6h post MnCl2 administration
At 6h post MnCl2 administration, the layered structure of the OB was clearly identifiable
with MR signal enhancement through Mn2+ accumulation in the glomerular layer (GL) and
the mitral cell layer (MCL) in the high resolution T1w MEMRI (Fig. 1B(ii)) with the
expanded view of the figure in the left panel of Fig. 1C. The external plexiform (EPL) and
granule cell (GrO) layers did not show clear signal enhancement. Cellular layers of the OB
in mice are detailed in a histological section figure (Fig. 1C, www.wikipedia.org) to
illustrate the matching structure in the T1w MEMRI.
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Quantitative measurement of axonal transport rate using T1-mapping
Figure 2 shows representative T1 maps (upper row, pseudo color) and T1w images (lower
row, gray color) of the OB of 3 mos old wt (Fig. 2A) and 3xTg-AD (Fig. 2B) mice at
baseline, and 1h, 6h, and 24h post MnCl2 administration through the nasal cavity. At 1h post
MnCl2 administration, a slight T1 reduction was observed in the medial and lateral regions
of the left OB in the T1 map of wt. The corresponding T1w signal enhancement was also
observed in the T1w image of wt. No discernable changes were detectable in either the T1
maps or T1w MRI of 3xTg-AD mice. At 6h and 24h, both wt and 3xTg-AD mice showed
clear T1 reductions (T1w MEMRI signal enhancement) at the medial, lateral and dorsal parts
of the left OB. The time course of R1 was calculated from the ROI placed mostly in the
glomerular layer of the lateral part of the OB (Square in Fig. 2A, top row). Group
comparisons of R1 in the OB of 3 mos old mice between wt and 3xTg-AD mice are shown
in Fig. 4C. R1 values of 3xTg-AD mice were significantly lower at 1h (wt: 0.82 ± 0.12 s-1,
3xTg-AD: 0.69 ± 0.04 s-1; p = 0.043), 6h (wt: 1.84 ± 0.27 s-1, 3xTg-AD: 1.31 ± 0.0.28 s-1; p
= 0.005) and 24h (wt: 1.76 ± 0.36 s-1, 3xTg-AD: 1.25 ± 0.24 s-1; p = 0.018) post MnCl2
administration, indicating lower axonal transport of Mn2+ in 3xTg-AD than that in wt mice.
Lower axonal transport rate in the OB of 3xTg-AD
An average ATRI of the OB was calculated from the difference between R1 values at 1h and
6h in the same manner as in Fig. 2C. Group comparisons between 3mos old 3xTg-AD and
wt showed that 3xTg-AD mice had a significantly lower axonal transport rate (p = 0.034)
(Fig. 3). Figure 3A shows T1 maps and the corresponding T1w MEMRI of the OB (slice
position ii in Fig. 1A) with the clear unilateral signal enhancement in the left OB of 3xTg-
AD at 6h post MnCl2 administration. The axonal transport rate remained lower in 3xTg-AD
mice compared to wt mice at 15 mos, although it did not reach statistical significance (p =
0.087). The overall ATRI of 3xTg-AD mice was lower by 27% at 3 mos and lower by 54%
at 15 mos compared to wt mice.
The effect of aging on the axonal transport rate was assessed in three age groups (2 mos, 3
mos, and 15 mos). The average ATRI fell with age for both wt and 3xTg-AD groups
although 3xTg-AD mice transport rates fell more in all age groups. The difference between
young mice (2 mos and 3 mos) and old mice was statistically significant in both groups
(3xTg-AD: p = 0.001 for 2 mos vs. 15 mos, and p = 0.028 for 3 mos vs. 15 mos; wt: p =
0.033 for 2 mos vs. 15 mos, and p = 0.017 for 3 mos vs. 15 mos). Age-dependent decreases
of the ATRI from 2 mos of age were 22% and 69% at 3 mos and 15 mos of age for 3xTg-
AD mice, respectively, while the decreases were 9% and 43% for wt mice.
Measurement of trans-synaptic axonal transport rate in the lateral olfactory tract
Figure 4A shows T1 maps and the corresponding T1w MEMRI of the LOT (slice position iii
in Fig. 1A) with the unilateral T1 reduction in the left LOT of 3xTg-AD at 24h post MnCl2
administration. At earlier time points (1h or 6h post MnCl2 administration), no signal
enhancement was observed in the LOT.
The ATRI was measured at the LOT in 2 mos, 3 mos and 15 mos old 3xTg-AD mice.
Overall the axonal transport deficits in the LOT were similar to transport deficits observed
in the OB of 3 mos and 15 mos mice. The results of the comparison indicate that a dramatic
axonal transport deficit occurred at 3 mos (p = 0.039) of age and persisted in older age mice
(15 mos) (p = 0.028) compared to age-matched wt mice (Fig. 4B). The difference between
young mice (2 mos and 3 mos) and old mice was statistically significant in 3xTg-AD mice
(p = 0.003 for 2 mos vs. 15 mos, and p = 0.016 for 3 mos vs. 15 mos), but there were no
differences in wt mice (p > 0.1). The age-dependent decreases of the ATRI from 2 mos
3xTg AD mice were 14% and 54% at 3 mos and 15 mos of age, respectively. Trans-synaptic
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transmission efficiency index of Mn2+ in 3xTg-AD mice did not differ from that of wt mice
in all age groups (p > 0.19).
Discussion
Early axonal transport deficit in the 3xTg-AD mouse brain
In this study, axonal transport deficits in 3xTg-AD mice preceded deposition of Aβ plaques
and neurofibrillary tangles. Our findings of the early axonal transport deficit in 3xTg-AD
mice at 3 mos of age are coincident with the timing of intraneuronal Aβ accumulation, as
3xTg-AD mice are known to develop this pathological lesion at 3 – 4 mos in the neocortex,
extracellular Aβ pathology such as Aβ plaque deposition at 5 – 6 mos in the frontal cortex,
and the Tau pathology at 12 mos of age (Oddo et al. 2003). In light of the recent
demonstration by Pigino and colleagues that intraneuronal Aβ, especially oligomers, can
induce fast axonal transport deficits in the giant squid axoplasm (Pigino et al. 2009), the
intraneuronal Aβ accumulation in 3xTg-AD mice at 3 – 4 mos of age may be a contributor
to the observed axonal transport deficits. Furthermore, the axonal transport deficits could be
linked to cognitive impairment observed in 3xTg-AD at the same age (Billings et al. 2005).
Early axonal transport deficits in 3xTg-AD were also consistent with previous findings in
Tg2576 mice in which axonal transport deficits occurred at 6 – 7 mos of age, prior to Aβ
plaque deposition (Smith et al. 2007).
The axonal transport deficits in 3xTg-AD persisted to the later age of 15 mos, the age range
in which both extracellular Aβ and Tau pathologies are known to be present (Oddo et al.
2003). Although extracellular Aβ and/or Tau pathology may not contribute to the initial
axonal transport deficits, it is highly probable that both pathologies contribute to the further
reduction of axonal transport rates at a later age compared to those at 3 mos of age.
Trans-synaptic axonal transport of Mn2+
The axonal transport in the LOT of 3xTg-AD mice was also impaired as observed in the OB
of 3 mos and 15 mos. Note that the ATRI in the LOT is an order of magnitude lower than
that in the OB. The ATRI reflects the rate of Mn2+ accumulation in each region of interest
and the amount of Mn2+ accumulation at a given time in each region depends on the
distance from the Mn2+ uptake site (i.e., turbinate) and the availability of Mn2+ in the
neurons for transport after the uptake. The longer axonal distances from the turbinate to the
LOT and the Mn2+ dilution factor at the OB as Mn2+ are transported from the OB to various
brain regions have contributed to the lower accumulation of Mn2+ in the LOT.
The transport deficits at the LOT could be caused either by slow movement of vesicles along
the axons or by low efficiency of synaptic transport of vesicles, since the ATRI at the
olfactory tracts includes contributions from (1) axonal transport into the OB, (2) synaptic
transmission from the olfactory sensory neurons to mitral cells at glomeruli in the OB and
(3) axonal transport to the LOT. Considering that there was no difference in trans-synaptic
transmission efficiency indices of Mn2+ (synaptic transmission from the olfactory sensory
neurons to mitral cells) between 3xTg-AD and wt mice in all age groups, the lower axonal
transport rate index at the LOT in 3xTg-AD is most likely due to slow axonal transport
within the neurons.
Quantitative measurement of T1 mapping at high magnetic field, 9.4 T
We have achieved quantitative axonal transport rate measurements in the mouse brain in
vivo using our T1 mapping method. One of the major challenges of T1 mapping in mice is
the long acquisition time when using multiple TR / flip angle sequences or conventional
single-slice Look-Locker sequences. Another challenge is the possible image distortion and/
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or signal dropout when echo planar imaging sequences are used to reduce the acquisition
time. To overcome these problems, we used our fast multi-slice Look-Locker method that
provided T1 mapping in less than 9 min. By using B1 corrected quantitative T1 mapping,
with an excellent image resolution (156 × 156 × 500 μm3) across the mouse brain we
visualized the T1 shortening in the OB and the LOT.
Significantly lower dose of MnCl2 for MEMRI
Mn2+ has proven to be useful in monitoring Ca2+ influx and measuring axonal transport
rates in biological research (Serrano et al. 2008; Smith et al. 2007); however it is important
to note that manganese is neurotoxic at high concentrations. Since the toxicity of manganese
is associated with high concentrations, it is imperative to reduce the dose to avoid possible
neurotoxicity, especially in longitudinal studies. In this study, we could lower the
concentration of MnCl2 to 20 times lower (<5% of the dosages) than those used in previous
studies (Serrano et al. 2008; Smith et al. 2007) with a sufficiently high contrast-to-noise
ratio (CNR). By allowing 6 hr of Mn2+ accumulation in the OB in conjunction with our T1
mapping method and high magnetic field, the detection sensitivity of MRI signal changes
was greatly enhanced. Thus, we were able to obtain robust detection of MEMRI signal
changes at this low total dose of Mn2+ and to quantify the axonal transport rates reliably.
When animals were subjected to multiple MEMRI sessions, the axonal transport rates were
consistent, and we did not observe any behavioral changes, suggesting no observable ill
effects from Mn2+ at the current dose.
Potential limitation of axonal transport measurement using MEMRI and future directions
Since MEMRI measurements rely on Mn2+ accumulation and its concentration in the OB,
the axonal transport rate measured using MEMRI methods may include other contributing
factors, such as uptake of Mn2+ in the olfactory sensory neurons in the turbinate, packaging
of Mn2+ into the vesicles, and cargo binding to the motor protein, kinesin. In this study, we
did not observe any difference in signal enhancement in the turbinate area between 3xTg-
AD and wt mice in all age groups demonstrating that uptake of Mn2+ in the olfactory
sensory neurons is largely identical. However, MEMRI does not provide any information
regarding packaging of Mn2+ and cargo binding. Therefore, the axonal transport indices
measured using MEMRI should be interpreted as an index for overall axonal transport
integrity rather than a simple rate of axonal cargo movement. Considering the fact that there
are multiple targets for disturbing axonal transport in neurodegenerative diseases including
AD, axonal transport rate measurement using MEMRI in vivo can be used to assess overall
integrity of axonal transport system that may be relevant to cognitive and behavioral
outcomes.
The current findings of the axonal transport deficit could be correlated with biochemical and
histochemical analysis results to associate with the presence of Aβ and tau pathology.
Further study is needed to understand the mechanisms responsible for early axonal transport
deficits in 3xTg-AD mice. In addition, the longitudinal axonal transport measurements
should be possible by taking advantage of lower MnCl2 dosage and T1 mapping techniques
to investigate the axonal transport deficits in disease progression and the effect of the drug
treatment in the same cohorts of animals.
Conclusion
This study demonstrates that high resolution quantitative MEMRI is a valuable method for
non-invasive measurements of axonal transport in the mouse brain. The combination of a
novel quantitative T1 mapping MEMRI technique, a high sensitivity RF coil set and high
magnetic field of 9.4 T, provided a robust measurement of R1 changes in OB and other parts
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of the brain as well as a visualization of cellular layers of the OB structure with high signal-
to-noise ratio. Thus, this in vivo MEMRI approach should enable us to investigate axonal
transport deficits in various transgenic mouse models of AD to evaluate the disease
progression and the effect of drug treatments. This study also reports quantitative
measurements of very early, yet subtle, axonal transport deficits in olfactory systems of
3xTg-AD mice. Our data suggest that accumulation of intra-neuronal Aβ rather than the
extra-cellular Aβ or abnormal Tau may initially lead to the axonal transport impairment.
However, further studies are needed to directly link intra-neuronal Aβ and axonal transport
deficits and to assess the effect of extracellular Aβ and Tau pathology on axonal transport.
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Figure 1. MEMRI of a 3xTg-AD mouse
(A) T1w high resolution coronal MEMRI (Top) and sagittal MRI (Bottom) of a 3xTg-AD
mouse showing slice positions of MEMRI data acquisition: (i) turbinate; (ii) olfactory bulb
(OB) and (iii) lateral olfactory tracks (LOT) at 6h post MnCl2 administration. (B)
Corresponding T1w high resolution (78 × 78 × 450 μm3) transverse images of (i) the
turbinate at 1h, (ii) the OB at 6h, and (iii) the LOT at 24h post MnCl2 administration. (C)
Extended view of the OB and a corresponding histological section of the OB illustrating the
layered structure of the different cell types: the glomerular layer (GL); mitral cell layer
(ML); external plexiform layer (EPL); and granule cell layer (GrO) [Image adapted from
Wikipedia, public domain]. “R” in Fig. 1A and 1B indicates the animal’s right and “L”
indicates the animal’s left.
Kim et al. Page 11













Figure 2. Quantification of the axonal transport rate
Two sets (A and B) of T1 maps with corresponding T1w images of the OB of 3 mos old wt
(A) and 3xTg-AD (B) mice at baseline, and 1h, 6h, and 24h post MnCl2 administration. The
small square in the T1 map (top row right most) indicates the ROI inside of which the ATRI
((R1(6h) – R1(1h))/5) of the OB was calculated. The gradient bars indicate the range of T1
values from 0 s to 2.3 s. “R” in Fig. 2A (top row left most) indicates the animal’s right and
“L” indicates the animal’s left; this orientation holds for all figures displayed. (C)
Longitudinal relaxation rate (R1) at the OB of 3 mos old mice at baseline, and 1h, 6h, and
24h post MnCl2 administration, quantified from the ROI shown in Fig. 2A. (*: p = 0.04 for
1h; **: p = 0.005 for 6h; ***: p = 0.02 for 24h; n = 8 for wt and n = 5 for 3xTg-AD)
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Figure 3. Axonal transport deficit in the OB
(A) T1 map with corresponding T1w MEMRI at the OB of a 3xTg-AD mouse at 2 mos of
age. MEMRI was performed at 6h post MnCl2 administration. A small square in the upper
panel shows an ROI where the ATRI in the OB (R1(6h)-R1(1h))/5) was obtained. The color
scale bar indicates the range of T1 values of 0 - 2.3 s. (B) Comparison of the ATRI in the
OB between wt and 3xTg-AD at 2 mos (n = 9 for wt, n = 8 for 3xTg-AD), 3 mos (n = 8 for
wt, n = 4 for 3xTg-AD) and 15 mos (n = 5 for wt, n = 6 for 3xTg-AD) of age at the OB.
(p=0.3 for 2 mos; *: p = 0.034 for 3 mos; p = 0.087 for 15 mos of age)
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Figure 4. Axonal transport deficits in the LOT
(A) T1 map with corresponding T1w MEMRI at the LOT of a 3xTg-AD mouse at 2 mos of
age. MEMRI was performed at 24h post MnCl2 administration. The circles indicate the LOT
area with unilateral enhancement. A small square in the upper panel shows an ROI in which
the ATRI ((R1(24h)-R1(Pre))/24) of the LOT was obtained. The color scale bar indicates the
range of T1 values of 0 - 2.3 s. (B) Comparison of the ATRI in the LOT between wt and
3xTg-AD at 2 mos (n = 9 for wt and n = 8 for 3xTg-AD), 3 mos (n = 8 for wt and n = 5 for
3xTg-AD) and 15 mos (n = 5 for wt and n = 6 for 3xTg-AD). (p=0.88 for 2 mos; *: p =
0.039 for 3 mos; **: p = 0.028 for 15 mos of age)
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